OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James Acquires 97,561 Shares

OncoCyte Co. (NASDAQ:OCX) CFO Andrea S. James bought 97,561 shares of OncoCyte stock in a transaction dated Friday, February 7th. The stock was purchased at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the purchase, the chief financial officer now owns 151,231 shares of the company’s stock, valued at approximately $310,023.55. This trade represents a 181.78 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OncoCyte Stock Performance

Shares of NASDAQ:OCX traded up $0.30 during trading on Tuesday, reaching $2.37. 362,186 shares of the company were exchanged, compared to its average volume of 58,483. The business’s fifty day simple moving average is $2.20 and its 200-day simple moving average is $2.71. OncoCyte Co. has a 12-month low of $1.92 and a 12-month high of $3.48.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The business had revenue of $0.12 million during the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same period in the previous year, the business posted ($0.57) earnings per share. As a group, equities analysts predict that OncoCyte Co. will post -2.57 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $4.25 price target on shares of OncoCyte in a report on Wednesday, November 13th. StockNews.com started coverage on OncoCyte in a report on Monday, January 13th. They issued a “sell” rating on the stock.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC lifted its position in OncoCyte Co. (NASDAQ:OCX) by 12.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.